92
Participants
Start Date
December 20, 2018
Primary Completion Date
April 26, 2021
Study Completion Date
April 26, 2021
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
NYU Langone Health, New York
Icahn School of Medicine at Mount Sinai, New York
Sing Chan, MD, Flushing
Thomas Jefferson University Hospital, Philadelphia
Xiaoli Ma, MD, Philadelphia
Digestive Disease Associates, Catonsville
Johns Hopkins University School of Medicine, Baltimore
University of Miami Hospital and Clinics, Miami
Coalition of Inclusive Medicine, Los Angeles
University of California Los Angeles, Los Angeles
Cedars-Sinai Medical Center, Beverly Hills
Research and Education, San Diego
Southern California Research Center, Coronado
Medical Associates Research Group, San Diego
Quest Clinical Research, San Francisco
Stanford University Medical Center, Stanford
Infectious Disease Care, Hillsborough
GI Research Institute, Vancouver
Toronto Liver Center, Toronto
Toronto General Hospital, Toronto
University of Hong Kong, Queen Mary Hospital, Hong Kong
Auckland Clinical Studies, Auckland
Waikato Hospital, Hamilton
King's College London, London
Lead Sponsor
Assembly Biosciences
INDUSTRY